VGX International Inc. (VGX Int'l) is a publicly-traded global biopharmaceutical company – listed on Korean Composite Stock Price Index (KOSPI: 011000). The Company is dedicated to the research and development of DNA vaccines for the therapeutic and preventative treatment of a large number of infectious diseases; among the pathogens targeted include both the avian and seasonal influenza.  In addition to the development of DNA vaccines and unlike most other vaccine companies, VGX Int'l manufactures and supplies high-end DNA plasmids to global companies and institutions through contract manufacturing services from the wholly owned U.S.-based subsidiary, VGXI, Inc. for a number of different uses including plasmids for clinical studies, animal studies, and other clinical, pre-clinical and diagnostic work. Dual business models by possessing the unique combination of vaccine development and manufacturing of DNA vaccine will provide VGX Int'l with the flexibility and resources to carry out the key clinical studies that will translate basic scientific innovation into commercial success.